Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NYSE MKT | Common Stock
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
It develops its products using its proprietary bacteriophage-based technology.
The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.
The company is based in Los Angeles, California.
Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 19, 25 | -0.23 Increased by +57.87% | -0.35 Increased by +33.80% |
| Nov 12, 24 | -0.15 Increased by +80.00% | -0.28 Increased by +46.43% |
| Aug 13, 24 | 0.25 Increased by +350.00% | -0.44 Increased by +156.82% |
| May 7, 24 | -0.69 Decreased by -72.50% | -0.31 Decreased by -122.58% |
| Mar 21, 24 | -0.55 Decreased by -89.66% | -0.35 Decreased by -57.14% |
| Nov 14, 23 | -0.75 Decreased by -212.50% | -0.31 Decreased by -141.94% |
| Aug 14, 23 | -0.10 Increased by +61.54% | -0.37 Increased by +72.97% |
| May 11, 23 | -0.40 Decreased by -33.33% | -0.32 Decreased by -25.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | 2.60 M Increased by +113.10% | Increased by +N/A% Increased by +N/A% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -5.48 M Increased by +82.41% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | 8.99 M Increased by +353.34% | Increased by +N/A% Increased by +N/A% |
| Mar 31, 24 | 966.00 K Increased by +21.36% | -25.02 M Decreased by -41.89% | Decreased by -2.59 K% Decreased by -16.92% |
| Dec 31, 23 | 1.53 M Increased by +45.39% | -19.85 M Decreased by -92.67% | Decreased by -1.30 K% Decreased by -32.52% |
| Sep 30, 23 | 1.23 M Decreased by -8.45% | -31.16 M Decreased by -262.13% | Decreased by -2.54 K% Decreased by -295.53% |
| Jun 30, 23 | 980.00 K Decreased by -47.96% | -3.55 M Increased by +61.49% | Decreased by -361.94% Increased by +26.00% |
| Mar 31, 23 | 796.00 K Increased by +N/A% | -17.63 M Decreased by -101.00% | Decreased by -2.22 K% Decreased by N/A% |